Harvard Bioscience (HBIO) Income from Discontinued Operations (2017 - 2018)

Harvard Bioscience's (HBIO) quarterly Income from Discontinued Operations came in at 442000.0 in Q4 2018, up 162.52% year-on-year from 168369.61 in Q4 2017, and up 4520.0% on a QoQ basis from 10000.0 in Q2 2018.

Harvard Bioscience (HBIO) Income from Discontinued Operations (2017 - 2018) Analysis & Trends

Harvard Bioscience (HBIO) has 2 years of Income from Discontinued Operations data on file, last reported at 442000.0 in Q4 2018.

  • On a quarterly basis, Income from Discontinued Operations rose 162.52% year-over-year to 442000.0 in Q4 2018; TTM through Sep 2019 was 442000.0, a 127.8% increase from a year earlier, with the FY2018 full-year figure at 441000.0, up 28.53% from the prior year.
  • Income from Discontinued Operations for Q4 2018 stood at 442000.0, up from 10000.0 in the prior quarter.
  • Over the last five years, Income from Discontinued Operations for HBIO reached as high as 442000.0 in Q4 2018 and fell as low as 873000.0 in Q1 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Intuitive Surgical 126.59 Bn 121.37 Bn 1.96 Bn -
2 Becton Dickinson 44.89 Bn 44.07 Bn 2.15 Bn -
3 Alcon 32.93 Bn 31.27 Bn 1.53 Bn -
4 Medline 32.81 Bn 30.58 Bn 1.84 Bn -
5 Resmed 29.39 Bn 27.73 Bn 890.98 Mn -
6 West Pharmaceutical Services 23.40 Bn 22.97 Bn 329.20 Mn -
7 Solventum 14.07 Bn 13.51 Bn 1.10 Bn -
8 Cooper Companies 13.78 Bn 13.64 Bn 735.40 Mn -
9 Align Technology 12.04 Bn 10.98 Bn 736.59 Mn -
10 Harvard Bioscience 27.35 Mn 20.25 Mn 12.24 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2018 442,000.00
Jun 30, 2018 -10,000.00
Mar 31, 2018 -873,000.00
Dec 31, 2017 -707,000.00
Sep 30, 2017 26,000.00
Jun 30, 2017 34,000.00
Mar 31, 2017 30,000.00